69 reports

  • Shire PLC's Major Product Approvals & Launches (2017)

Xiidra® (lifitegrast ophthalmic solution ##%), a twice-daily eye drop solution indicated for the treatment of the signs and symptoms of dry eye disease in adults has been approved in Canada.

  • Blood Disease
  • World
  • Bayer AG
  • Novo Nordisk Group
  • Pfizer Inc.

These areas are in (##) rare diseases (##) retinal diseases and (##) hemophilia.

  • Blood Disease
  • General Medicine And Specialty Medicine
  • Casebia Therapeutics LLP
  • Editas Medicine, Inc.
  • Novartis AG

You can easily book an appointment with one online.

  • General Medicine And Specialty Medicine
  • United States
  • Forecast
  • Carl Zeiss Meditec AG
  • Cianna Medical, Inc.
  • ORGAN TRANSPLANTATION

Corneal eye disease, which is the fourth most common cause of blindness and affects more than ## million people worldwide, require cornea transplantation.

  • General Medicine And Specialty Medicine
  • CareDx, Inc.
  • Illumina, Inc.
  • Immucor, Inc.
  • Thermo Fisher Scientific, Inc.

ICAM-## may be overexpressed in corneal and conjunctival tissues in dry eye disease.

  • Blood Disease
  • General Medicine And Specialty Medicine
  • Therapy
  • United States
  • Shire plc

THEIA-## is a multi-centre, randomized, double-masked, placebo-controlled Phase IIb/ III study that will enroll approximately ## adult patients with moderate to severe dry eye disease.

  • Blood Disease
  • Cancer
  • General Medicine And Specialty Medicine
  • United States
  • Product Initiative

The NFS remained stable in both patients over one year, suggesting a durable halt in disease progression.

  • Blood Disease
  • Endocrine Disease
  • General Medicine And Specialty Medicine
  • Therapy
  • Ampio Pharmaceuticals, Inc.

To date, these diseases have been treated with a ' one size fits all' approach, despite there being significant variation in disease course between patients with the same disease.

  • Blood Disease
  • Cancer
  • General Medicine And Specialty Medicine
  • United States
  • Company

ONE DROP OF ## G/ ML LUBRICIN IS EFFECTIVE IN REDUCING THE INSTANTANEOUS SYMPTOMS OF DRY EYE DISEASE FOR UP TO ## MINUTES.

  • Blood Disease
  • General Medicine And Specialty Medicine
  • Hospital
  • Therapy
  • TaiwanJ Pharmaceuticals Co., Ltd.

Its marketed and pipeline products are focused on helping patients suffering with eye diseases, cancer, allergic and inflammatory diseases, metabolic and cardiovascular diseases, infectious diseases, neuromuscular diseases, and rare diseases.

  • Blood Disease
  • Cancer
  • General Medicine And Specialty Medicine
  • Australia
  • United States

SR One Ltd.

  • Blood Disease
  • General Medicine And Specialty Medicine
  • Pharmaceutical
  • Therapy
  • Biogen Idec Inc.

The acquisition would help the company deliver medicine to patients suffering from a variety of eye diseases, while also laying critical groundwork for future, potential front-of-the-eye pipeline products that Novartis has in development.

  • Blood Disease
  • General Medicine And Specialty Medicine
  • Therapy
  • World
  • Novartis AG

Its marketed and pipeline products are focused on helping patients suffering with eye diseases, cancer, allergic and inflammatory diseases, metabolic and cardiovascular diseases, infectious diseases, neuromuscular diseases, and rare diseases.

  • Blood Disease
  • Chronic Disease
  • General Medicine And Specialty Medicine
  • United States
  • Product Initiative

Its lead product candidate Palovarotene is used for the treatment of fibrodysplasia ossificans progressiva (FOP), dry eye disease and multiple osteochondromas (MO).

  • Blood Disease
  • General Medicine And Specialty Medicine
  • United States
  • Product Initiative
  • BioCryst Pharmaceuticals, Inc.
  • Pipeline by Evec Inc, H2 2018
  • Pipeline by Ribomic Inc, H2 2018

The company' s products are used to treat pain, sepsis, lung fibrosis and other organ fibrosis, bone diseases, and eye diseases and inflammatory disorders.

  • Blood Disease
  • General Medicine And Specialty Medicine
  • Therapy
  • Product Initiative
  • Cantex Pharmaceuticals, Inc.

Its lead product candidate Palovarotene is used for the treatment of fibrodysplasia ossificans progressiva (FOP), dry eye disease and multiple osteochondromas (MO).

  • Blood Disease
  • Therapy
  • United States
  • Product Initiative
  • BioCryst Pharmaceuticals, Inc.
  • PIPELINE BY SCHOLAR ROCK INC, H1 2020
  • PIPELINE BY REGENERON PHARMACEUTICALS INC, H1 2020

Its marketed and pipeline products are focused on helping patients suffering with eye diseases, cancer, allergic and inflammatory diseases, metabolic and cardiovascular diseases, infectious diseases, neuromuscular diseases, and rare diseases.

  • Blood Disease
  • Therapy
  • United States
  • Product Initiative
  • Acceleron Pharma, Inc.
  • PIPELINE BY REGENERON PHARMACEUTICALS INC, H2 2019
  • PIPELINE BY PFIZER INC, H2 2019

Its marketed and pipeline products are focused on helping patients suffering with eye diseases, cancer, allergic and inflammatory diseases, metabolic and cardiovascular diseases, infectious diseases, neuromuscular diseases, and rare diseases.

  • Blood Disease
  • Therapy
  • United States
  • Product Initiative
  • Acceleron Pharma, Inc.
  • IDIOPATHIC THROMBOCYTOPENIC PURPURA (IMMUNE THROMBOCYTOPENIC PURPURA) - PIPELINE BY GENZYME CORP, H1 2020
  • PROTALEX INC

The company' s products are used in treatment of autoimmune diseases, dry eye diseases, and recurrent and intractable cancer.

  • Blood Disease
  • General Medicine And Specialty Medicine
  • Therapy
  • United States
  • Rigel Pharmaceuticals, Inc.
  • Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Genzyme Corp, H2 2019
  • Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Qilu Pharmaceutical Co Ltd, H2 2019

The company' s products are used in treatment of autoimmune diseases, dry eye diseases, and recurrent and intractable cancer.

  • Blood Disease
  • General Medicine And Specialty Medicine
  • Therapy
  • United States
  • Rigel Pharmaceuticals, Inc.
  • VASO-OCCLUSIVE CRISIS ASSOCIATED WITH SICKLE CELL DISEASE - PIPELINE BY NUVOX PHARMA LLC, H1 2020
  • VASO-OCCLUSIVE CRISIS ASSOCIATED WITH SICKLE CELL DISEASE - PIPELINE BY PROLONG PHARMACEUTICALS LLC, H1 2020

The company also conducts research and development of drugs for the ultrasound contrast, eye disease and wound healing.

  • Blood Disease
  • General Medicine And Specialty Medicine
  • United States
  • Product Initiative
  • AstraZeneca PLC
  • PIPELINE BY TAIHO PHARMACEUTICAL CO LTD, H1 2018
  • PIPELINE BY RIGEL PHARMACEUTICALS INC, H1 2018

The company also provides TOP## a candidate used in treatment of dry eye diseases.

  • Blood Disease
  • General Medicine And Specialty Medicine
  • Pharmaceutical
  • United States
  • Product Initiative
  • KM BIOLOGICS CO LTD
  • VASO-OCCLUSIVE CRISIS ASSOCIATED WITH SICKLE CELL DISEASE - PIPELINE BY NOVARTIS AG, H2 2019

The company also conducts research and development of drugs for the ultrasound contrast, eye disease and wound healing.

  • Blood Disease
  • General Medicine And Specialty Medicine
  • United States
  • Product Initiative
  • Pfizer Inc.

The company' s six US FDA-approved medicines and product candidates in development help patients with eye diseases, asthma, pain, cancer and heart, allergic, inflammatory and infectious diseases.

  • Blood Disease
  • Therapy
  • United States
  • Product Initiative
  • Acceleron Pharma, Inc.

The drug candidate is in preclinical stage of development for eye related diseases in Japan.

  • Blood Disease
  • General Medicine And Specialty Medicine
  • Therapy
  • United States
  • Incyte Corporation

Its marketed and pipeline products are focused on helping patients suffering with eye diseases, cancer, allergic and inflammatory diseases, metabolic and cardiovascular diseases, infectious diseases, neuromuscular diseases, and rare diseases.

  • Blood Disease
  • General Medicine And Specialty Medicine
  • United States
  • Product Initiative
  • Incyte Corporation

The company' s six US FDA-approved medicines and product candidates in development help patients with eye diseases, asthma, pain, cancer and heart, allergic, inflammatory and infectious diseases.

  • Blood Disease
  • General Medicine And Specialty Medicine
  • Pharmaceutical
  • United States
  • Bayer AG

In 2009, Apex Therapeutics, Inc. was awarded research grant of USD ##, ## from National Eye Institute (##R##EY##-##) for the project entitled Redox protein APE/ REF-## as a target for Age- Related Macular Degeneration (AMD).

  • Blood Disease
  • General Medicine And Specialty Medicine
  • United States
  • Company
  • Product Initiative

The organization is developing medicines for rare neuromuscular diseases, liver diseases, blood and eye disorders.

  • Blood Disease
  • Therapy
  • United States
  • Company Operations
  • Spark Therapeutics
  • HEMOPHILIA A (FACTOR VIII DEFICIENCY) - PIPELINE BY GENERATION BIO CORP, H2 2019
  • HEMOPHILIA A (FACTOR VIII DEFICIENCY) - PIPELINE BY GC PHARMA, H2 2019

Generation Bio researches and develops medicines in the areas of genetic diseases including liver, eye, lung diseases, central nervous system and others.

  • Blood Disease
  • General Medicine And Specialty Medicine
  • United States
  • Company
  • Product Initiative